not vested
In other action, 3SBio, China's second largest biotechnological medicine producer by sales in 2013, has been oversubscribed by 2.7 times.
The company opened its retail book yesterday, receiving HK$2.08 billion worth of margin orders from eight brokerages.
The Shenyang-based firm is seeking up to HK$5.52 billion through its Hong Kong float, after delisting from the Nasdaq two years ago.
It will price the SHARES between HK$8.30 to HK$9.10, representing an entry fee of HK$4,595.85 for a board lot of 500 shares.
3SBio plans to use 45 percent of net proceeds to acquire medical products, 15 percent to strengthen marketing, 15 percent to improve production capacity, 15 percent on research and development and the rest on working capital. TRADINGwill begin on June 11.
Source: The Standard HK